Fremont, California-based cell analysis solutions company, Cytek Biosciences, has announced that it will report its financial results for the first quarter of 2023 after the market closes on Tuesday, May 9th, 2023. The company’s management will discuss its results, business developments and outlook in a corresponding conference call starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, which will be webcast live on the ‘Investors’ section of the Cytek Biosciences website at investors.cytekbio.com.
Investors have been eagerly anticipating the company’s financial results as Cytek Biosciences recently acquired DiaSorin’s Flow Cytometry & Imaging Business unit, which has added Guava flow cytometers and Amnis imaging flow cytometers to its suite of cell analysis tools. Last year, the cell analysis solutions company also announced the launch of its advanced Aurora CS cell sorter, which utilizes its patented Full Spectrum Profiling (FSP) technology to achieve high-resolution, high-content and high-sensitivity cell analysis with precision and sensitivity.
Also Read:
Cytek Biosciences’ industry-leading FSP platform includes its core instruments- the Aurora and Northern Lights systems- reagents, software and services to provide an integrated suite of solutions for its customers. The company’s products, other than Northern Lights CLC system and some reagents for use therewith which have obtained regulatory approval, are for research use only and not for use in diagnostic procedures. The company recommends that customers contact local sales representatives to ascertain the status of local regulatory approval.
Aside from filings with the Securities and Exchange Commission (SEC), public conference calls and webcasts, Cytek Biosciences utilizes its website, LinkedIn page and corporate Twitter account as channels of distribution of information about the company, its products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters.
Also Read:
Cytek Biosciences’ foray into the cell analysis solutions industry has been successful, with revenue increasing year-on-year. The company has been recognised for its breakthrough technology and was included in Fast Company’s 100 Best Workplaces for Innovators list in 2020, as well as receiving the Digital Edge 50 Award for its FSP technology last year.
Headquartered in Fremont, California, Cytek Biosciences has offices and distribution channels across the globe. The company’s products are relied upon by researchers and scientists in academic, pharmaceutical and biotech institutions, as well as contract research organizations and clinical laboratories.
Also Read:
Paul D. Goodson, Head of Investor Relations at Cytek Biosciences, is the company’s designated point of contact for investor relations, while Stephanie Olsen from Lages & Associates is the company’s media contact.
In Other News Around the World: